Trials / Unknown
UnknownNCT03875183
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Innolife Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INL1 | Capsules |
| OTHER | Placebo | Capsules |
Timeline
- Start date
- 2020-01-20
- Primary completion
- 2022-12-01
- Completion
- 2023-01-01
- First posted
- 2019-03-14
- Last updated
- 2022-03-31
Locations
13 sites across 2 countries: United States, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03875183. Inclusion in this directory is not an endorsement.